Cargando…

Current Technologies for RNA-Directed Liquid Diagnostics

SIMPLE SUMMARY: The discovery of nucleic acids in blood has rapidly led into the development of methods for their isolation, characterisation and validation in the context of liquid biopsy. In this emerging field, miRNAs are promising biomarkers for the detection of solid tumours in the body fluids...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Dominguez, Maria Victoria, Zottel, Alja, Šamec, Neja, Jovčevska, Ivana, Dincer, Can, Kahlert, Ulf Dietrich, Nickel, Ann-Christin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534233/
https://www.ncbi.nlm.nih.gov/pubmed/34680210
http://dx.doi.org/10.3390/cancers13205060
_version_ 1784587506219483136
author Martinez-Dominguez, Maria Victoria
Zottel, Alja
Šamec, Neja
Jovčevska, Ivana
Dincer, Can
Kahlert, Ulf Dietrich
Nickel, Ann-Christin
author_facet Martinez-Dominguez, Maria Victoria
Zottel, Alja
Šamec, Neja
Jovčevska, Ivana
Dincer, Can
Kahlert, Ulf Dietrich
Nickel, Ann-Christin
author_sort Martinez-Dominguez, Maria Victoria
collection PubMed
description SIMPLE SUMMARY: The discovery of nucleic acids in blood has rapidly led into the development of methods for their isolation, characterisation and validation in the context of liquid biopsy. In this emerging field, miRNAs are promising biomarkers for the detection of solid tumours in the body fluids of cancer patients. This review gives an overview of the current methods of isolating circulating free and exosomal miRNAs, the advantages and disadvantages of the methods and the different techniques for miRNA quantification. At the end, the clinical relevance and market value of RNA-based liquid biopsy are explored and discussed with respect to the field of precision medicine. ABSTRACT: There is unequivocal acceptance of the variety of enormous potential liquid nucleic acid-based diagnostics seems to offer. However, the existing controversies and the increased awareness of RNA-based techniques in society during the current global COVID-19 pandemic have made the readiness of liquid nucleic acid-based diagnostics for routine use a matter of concern. In this regard—and in the context of oncology—our review presented and discussed the status quo of RNA-based liquid diagnostics. We summarized the technical background of the available assays and benchmarked their applicability against each other. Herein, we compared the technology readiness level in the clinical context, economic aspects, implementation as part of routine point-of-care testing as well as performance power. Since the preventive care market is the most promising application sector, we also investigated whether the developments predominantly occur in the context of early disease detection or surveillance of therapy success. In addition, we provided a careful view on the current biotechnology investment activities in this sector to indicate the most attractive strategies for future economic success. Taken together, our review shall serve as a current reference, at the interplay of technology, clinical use and economic potential, to guide the interested readers in this rapid developing sector of precision medicine.
format Online
Article
Text
id pubmed-8534233
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85342332021-10-23 Current Technologies for RNA-Directed Liquid Diagnostics Martinez-Dominguez, Maria Victoria Zottel, Alja Šamec, Neja Jovčevska, Ivana Dincer, Can Kahlert, Ulf Dietrich Nickel, Ann-Christin Cancers (Basel) Review SIMPLE SUMMARY: The discovery of nucleic acids in blood has rapidly led into the development of methods for their isolation, characterisation and validation in the context of liquid biopsy. In this emerging field, miRNAs are promising biomarkers for the detection of solid tumours in the body fluids of cancer patients. This review gives an overview of the current methods of isolating circulating free and exosomal miRNAs, the advantages and disadvantages of the methods and the different techniques for miRNA quantification. At the end, the clinical relevance and market value of RNA-based liquid biopsy are explored and discussed with respect to the field of precision medicine. ABSTRACT: There is unequivocal acceptance of the variety of enormous potential liquid nucleic acid-based diagnostics seems to offer. However, the existing controversies and the increased awareness of RNA-based techniques in society during the current global COVID-19 pandemic have made the readiness of liquid nucleic acid-based diagnostics for routine use a matter of concern. In this regard—and in the context of oncology—our review presented and discussed the status quo of RNA-based liquid diagnostics. We summarized the technical background of the available assays and benchmarked their applicability against each other. Herein, we compared the technology readiness level in the clinical context, economic aspects, implementation as part of routine point-of-care testing as well as performance power. Since the preventive care market is the most promising application sector, we also investigated whether the developments predominantly occur in the context of early disease detection or surveillance of therapy success. In addition, we provided a careful view on the current biotechnology investment activities in this sector to indicate the most attractive strategies for future economic success. Taken together, our review shall serve as a current reference, at the interplay of technology, clinical use and economic potential, to guide the interested readers in this rapid developing sector of precision medicine. MDPI 2021-10-10 /pmc/articles/PMC8534233/ /pubmed/34680210 http://dx.doi.org/10.3390/cancers13205060 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Martinez-Dominguez, Maria Victoria
Zottel, Alja
Šamec, Neja
Jovčevska, Ivana
Dincer, Can
Kahlert, Ulf Dietrich
Nickel, Ann-Christin
Current Technologies for RNA-Directed Liquid Diagnostics
title Current Technologies for RNA-Directed Liquid Diagnostics
title_full Current Technologies for RNA-Directed Liquid Diagnostics
title_fullStr Current Technologies for RNA-Directed Liquid Diagnostics
title_full_unstemmed Current Technologies for RNA-Directed Liquid Diagnostics
title_short Current Technologies for RNA-Directed Liquid Diagnostics
title_sort current technologies for rna-directed liquid diagnostics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534233/
https://www.ncbi.nlm.nih.gov/pubmed/34680210
http://dx.doi.org/10.3390/cancers13205060
work_keys_str_mv AT martinezdominguezmariavictoria currenttechnologiesforrnadirectedliquiddiagnostics
AT zottelalja currenttechnologiesforrnadirectedliquiddiagnostics
AT samecneja currenttechnologiesforrnadirectedliquiddiagnostics
AT jovcevskaivana currenttechnologiesforrnadirectedliquiddiagnostics
AT dincercan currenttechnologiesforrnadirectedliquiddiagnostics
AT kahlertulfdietrich currenttechnologiesforrnadirectedliquiddiagnostics
AT nickelannchristin currenttechnologiesforrnadirectedliquiddiagnostics